Updates with share moves

** Shares of Telix Pharmaceuticals TLX.AX rise 2.8% to A$27.44

** Morningstar analysts expect TLX to receive a delayed regulatory approval, instead of a denial, for co's Pixclara, an imaging agent for glioma brain cancer

** Telix said on Monday that the U.S. Food and Drug Administration declined to approve its new drug application for Pixclara

** The FDA has requested additional clinical evidence to progress the application

** Brokerage expects the product to make first sales and contribute to earnings from 2026, instead of 2025

** FOrecasts no material effect on co over the medium term

** Stock rated "buy" on average; median price target stands at A$35, per data compiled by LSEG

** Stock last up 11.3%, YTD

(Reporting by Jasmeen Ara Shaikh in Bengaluru)

((JasmeenAraIslam.Shaikh@thomsonreuters.com))